Tier 3 — preclinical

Effect of a Daily Collagen Peptide Supplement on Digestive Symptoms in Healthy Women: 2-Phase Mixed Methods Study

Mariette Abrahams, Rochez O'Grady, Janne Prawitt
JMIR Formative Research 2022 6(5):e36339

Bibliography

PubMed
PMID 35639457
PubMed Central
PMC9198822
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Research industry links: one coauthor employed by collagen manufacturer Rousselot.
Competing interests
Janne Prawitt employed by Rousselot BV; formulation is Peptan.

Study snapshot

DesignProspective open-label single-arm digital feasibility pilot following exploratory qualitative phase
ModelOtherwise healthy women with BMI >25 kg/m² and self-reported digestive symptoms
Sample40 enrolled; 14 (35%) completed full 8-week supplementation
Intervention20 g/day Peptan collagen peptides (two divided doses); no concurrent placebo control
Duration2-week symptom baseline plus 8-week intervention
EndpointsSelf-reported bloating and digestive symptoms; Adherence; Study feasibility

What the study showed, in plain terms

Among 14 completers of an open-label collagen pilot, 13 reported improved digestive symptoms. However, attrition was 65% and there was no placebo group, so causation and generalizability are highly uncertain.

Key findings

13 of 14 completers (93%) reported less digestive discomfort after an 8-week 20-g/day intervention; trial was designed chiefly to test digital-study feasibility.

What this study can and cannot tell us

No placebo/control group, high attrition (26/40), self-report outcomes, limited to women with BMI >25, tested Peptan 20 g not DoNotAge 10 g. Insufficient to substantiate leaky-gut, barrier repair or IBS treatment claims.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified